A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...
Learn how intelligent medical records enhance patient care, streamline workflows, and improve healthcare outcomes through ...
Explore a comparative study on ESR1 mutation testing using dPCR and NGS. Understand the strengths and applications of each ...
Explore the FDA fast track oncology drugs granted in September 2026, advancing treatments for various cancer types.
On Oct. 2, the U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca) for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who ...
Recent headlines on leadership appointments, executive transitions and notable recognitions spotlight the leaders helping to ...
At WCLC 2026, three thoracic oncologists discuss first-line regimen selection, subcutaneous dosing, dermatologic prophylaxis, and dose modifications in EGFR-mutant NSCLC. Subcutaneous amivantamab has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results